company background image
CLGN logo

CollPlant Biotechnologies NasdaqGM:CLGN Stock Report

Last Price

US$3.72

Market Cap

US$43.0m

7D

-1.2%

1Y

-33.6%

Updated

06 Feb, 2025

Data

Company Financials +

CollPlant Biotechnologies Ltd.

NasdaqGM:CLGN Stock Report

Market Cap: US$43.0m

CLGN Stock Overview

A regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. More details

CLGN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

CollPlant Biotechnologies Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for CollPlant Biotechnologies
Historical stock prices
Current Share PriceUS$3.72
52 Week HighUS$6.75
52 Week LowUS$3.24
Beta0.63
1 Month Change-16.90%
3 Month Change-5.20%
1 Year Change-33.64%
3 Year Change-63.10%
5 Year Change-66.37%
Change since IPO-79.87%

Recent News & Updates

We're Interested To See How CollPlant Biotechnologies (NASDAQ:CLGN) Uses Its Cash Hoard To Grow

Aug 20
We're Interested To See How CollPlant Biotechnologies (NASDAQ:CLGN) Uses Its Cash Hoard To Grow

Recent updates

We're Interested To See How CollPlant Biotechnologies (NASDAQ:CLGN) Uses Its Cash Hoard To Grow

Aug 20
We're Interested To See How CollPlant Biotechnologies (NASDAQ:CLGN) Uses Its Cash Hoard To Grow

We're Interested To See How CollPlant Biotechnologies (NASDAQ:CLGN) Uses Its Cash Hoard To Grow

Feb 03
We're Interested To See How CollPlant Biotechnologies (NASDAQ:CLGN) Uses Its Cash Hoard To Grow

Is CollPlant Biotechnologies (NASDAQ:CLGN) In A Good Position To Deliver On Growth Plans?

Nov 02
Is CollPlant Biotechnologies (NASDAQ:CLGN) In A Good Position To Deliver On Growth Plans?

CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) Shares Lagging The Industry But So Is The Business

Sep 06
CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) Shares Lagging The Industry But So Is The Business

Here's Why We're Watching CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation

Jul 14
Here's Why We're Watching CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation

Here's Why We're Not Too Worried About CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation

Mar 02
Here's Why We're Not Too Worried About CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation

Companies Like CollPlant Biotechnologies (NASDAQ:CLGN) Are In A Position To Invest In Growth

Nov 10
Companies Like CollPlant Biotechnologies (NASDAQ:CLGN) Are In A Position To Invest In Growth

CollPlant Non-GAAP EPS of -$0.36, revenue of $0.07M

Aug 25

We Think CollPlant Biotechnologies (NASDAQ:CLGN) Can Afford To Drive Business Growth

Jul 22
We Think CollPlant Biotechnologies (NASDAQ:CLGN) Can Afford To Drive Business Growth

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 22
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

CollPlant Biotechnologies - A Cheap, Game-Changing Bio-Printing Platform Company

Aug 05

Why We Think Shareholders May Be Considering Bumping Up CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) CEO Compensation

Jul 29
Why We Think Shareholders May Be Considering Bumping Up CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) CEO Compensation

The Strong Earnings Posted By CollPlant Biotechnologies (NASDAQ:CLGN) Are A Good Indication Of The Strength Of The Business

Jun 09
The Strong Earnings Posted By CollPlant Biotechnologies (NASDAQ:CLGN) Are A Good Indication Of The Strength Of The Business

Shareholder Returns

CLGNUS BiotechsUS Market
7D-1.2%3.5%0.6%
1Y-33.6%2.9%22.4%

Return vs Industry: CLGN underperformed the US Biotechs industry which returned 2.9% over the past year.

Return vs Market: CLGN underperformed the US Market which returned 22.4% over the past year.

Price Volatility

Is CLGN's price volatile compared to industry and market?
CLGN volatility
CLGN Average Weekly Movement7.6%
Biotechs Industry Average Movement11.4%
Market Average Movement6.4%
10% most volatile stocks in US Market18.8%
10% least volatile stocks in US Market3.2%

Stable Share Price: CLGN has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: CLGN's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198175Yehiel Talwww.collplant.com

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company’s products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures.

CollPlant Biotechnologies Ltd. Fundamentals Summary

How do CollPlant Biotechnologies's earnings and revenue compare to its market cap?
CLGN fundamental statistics
Market capUS$42.96m
Earnings (TTM)-US$17.42m
Revenue (TTM)US$650.00k

65.5x

P/S Ratio

-2.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CLGN income statement (TTM)
RevenueUS$650.00k
Cost of RevenueUS$2.13m
Gross Profit-US$1.48m
Other ExpensesUS$15.94m
Earnings-US$17.42m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.52
Gross Margin-227.08%
Net Profit Margin-2,680.00%
Debt/Equity Ratio0%

How did CLGN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 00:44
End of Day Share Price 2025/02/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CollPlant Biotechnologies Ltd. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason KolbertD. Boral Capital LLC.
Linda PomeroyEdison Investment Research
Swayampakula RamakanthH.C. Wainwright & Co.